Hospital Infection Therapeutics Market for Hospital-Acquired Pneumonia, Urinary Tract Infections
MRRSE has announced the addition of the “Hospital Infection Therapeutics Market (Drug Type: Antibacterial, Antiviral and Antifungal Drugs; Infection Type: Hospital-Acquired Pneumonia, Urinary Tract Infections) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020” report to their offering.
Hospital-acquired infections are caused by bacterial, fungal, and viral pathogens. A majority of cases of hospital infections start from the intensive care units (ICUs). A large number of antimicrobial drugs have proven their competence in the treatment of a wide range of hospital infections.
This report predicts and analyzes the market for hospital infection therapeutics, on a regional and global level. The prediction is offered in terms of volume as well as revenue of the hospital infection therapeutics market in the forecasting horizon between 2014 and 2020. This research report includes the factors that fuel the market, as well as the restraining factors that will adversely influence the growth of the market during the forecast horizon.
Read Complete Report @ http://www.mrrse.com/hospital-infection-therapeutics
In order to achieve a more crisp understanding of the hospital infection therapeutics market, TMR analysts have demonstrated an in-depth analysis of the value chain of the market. The business methodologies incorporated by the key players in the market are also elaborated in this report. The prominent players in the hospital infection therapeutics market, along with their competitive profiling as well as independent market shares across the four major geographical regions, have been included in this report. To get a know-how of the market dynamics, an evaluation of market attractiveness has also been incorporated in this study.
Overview of the Hospital Infection Therapeutics Market
The patients undergoing treatments in hospitals can develop infections in the course of their stay in the hospitals. These infections are called as hospital infections or hospital-acquired infections (HAI). These infections spread in healthcare environments such as outpatient surgery centers, rehabilitation centers, dialysis centers, hospitals, and nursing homes.
Inquiry on this report @ http://www.mrrse.com/enquiry/952
On the basis of the type of drug, the market for hospital infection therapeutics is segmented into antibacterial drugs, antifungal drugs, and antiviral drugs. The antibacterial drugs segment constituted the biggest share – 70.7% – in 2013 in the global market for hospital infection therapeutics. The antibacterial drugs segment is also anticipated to be the most swiftly developing segment in the market for global hospital infection in the forecast horizon from 2014 to 2020.
In terms of major types of infections, the market for hospital infection therapeutics is segmented into gastrointestinal disorders, bloodstream infections, hospital-acquired pneumonia (HAP), surgical site infections, urinary tract infections, and other hospital infections. The largest share in the global hospital infection therapeutics market was held by the hospital-acquired pneumonia segment in 2013, which represented more than 20% of the overall market. However, the segment of urinary tract infections is projected to expand at a rapid rate in the coming future.
Get a Free Sample Copy of the Report @ http://www.mrrse.com/sample/952
On the basis of geography, the global hospital infection therapeutics market has been segmented into Europe, North America, Asia Pacific, and Rest of the World (RoW). On the basis of revenue, the market for hospital infection therapeutics was led by North America in 2013. After North America, the second biggest regional market was Europe. However, the hospital infection therapeutics market in Asia Pacific is predicted to witness the highest rate of growth throughout the forecast horizon.
The increase in the geriatric population, improved healthcare awareness, therapeutic drugs being highly in demand, and high occurrence of hospital infections are the key factors that stimulate the growth of the global hospital infection therapeutics market. Key factors that impede the growth of this market include rise in infection control, soaring number of multidrug-resistant bacterial strains, and hospital surveillance programs in emerging economies, which are leading to a reduced occurrence of hospital infections.
Key players in the Hospital Infection Therapeutics Market
AstraZeneca plc, Actavis plc, Bayer AG, Cubist Pharmaceuticals, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Merck & Co., Inc., Sanofi, Johnson & Johnson Services, Inc., and Pfizer, Inc. are amongst the prominent players in the hospital infection therapeutics market.
Major geographies analyzed under this research report are:
This report gives you access to decisive data such as:
Key highlights of this report:
Source: Free Articles from ArticlesFactory.com
ABOUT THE AUTHOR
MRRSE stands for Market Research Reports Search Engine, the largest online catalog of latest market research reports based on industries, companies, and countries. MRRSE sources thousands of industry reports, market statistics, and company profiles from trusted entities and makes them available at a click. Besides well-known private publishers, the reports featured on MRRSE typically come from national statistics agencies, investment agencies, leading media houses, trade unions, governments, and embassies.